Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transplantation for amyloidosis.

Morie A Gertz1, Martha Q Lacy, Angela Dispenzieri

  • 1Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA. gertz.morie@mayo.edu

Current Opinion in Oncology
|February 3, 2007
PubMed
Summary

High-dose chemotherapy and stem cell transplantation show promise for immunoglobulin light-chain amyloidosis patients. Response rates correlate with survival, though large trials are pending.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.

Circulation·2018
Same author

Publisher Correction: The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.

Nature reviews. Nephrology·2018
Same author

Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay.

Blood·2018
Same author

Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome.

Blood cancer journal·2018
Same author

Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2018
Same author

Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma.

American journal of hematology·2018

Area of Science:

  • Hematology
  • Oncology
  • Stem Cell Transplantation

Background:

  • High-dose chemotherapy is increasingly utilized for immunoglobulin light-chain amyloidosis (AL amyloidosis) management.
  • AL amyloidosis is a plasma cell disorder causing organ damage due to amyloid deposition.

Purpose of the Study:

  • To review outcomes of patients treated with high-dose chemotherapy and stem cell transplantation.
  • To analyze engraftment data and predictors of early mortality in AL amyloidosis.

Main Methods:

  • Retrospective review of nearly 300 patients treated at Mayo Clinic.
  • Literature review of recent studies on high-dose therapy and stem cell transplantation for AL amyloidosis.

Main Results:

  • Outcomes, engraftment data, and early mortality predictors were analyzed.

Related Experiment Videos

  • While response rates are high, a definitive survival benefit requires Phase III clinical trial verification.

    • Conclusions:

    • Partial and complete response rates are significant prognosticators of survival in AL amyloidosis.
    • High-dose therapy combined with stem cell transplantation yields higher response rates.